CanSino Biologics Inc. (HKG:6185)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 11.88B -33.1% |
| Revenue (ttm) | 1.43B +33.5% |
| Net Income | 46.91M |
| EPS | n/a |
| Shares Out | 247.04M |
| PE Ratio | 253.26 |
| Forward PE | 25.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,273,654 |
| Open | 26.80 |
| Previous Close | 26.84 |
| Day's Range | 25.16 - 27.30 |
| 52-Week Range | 19.22 - 55.85 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 47.54 (+84.26%) |
| Earnings Date | Aug 27, 2026 |
About CanSino Biologics
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine f... [Read more]
Analyst Summary
According to 4 analysts, the average rating for 6185 stock is "Strong Buy." The 12-month stock price target is $47.54, which is an increase of 84.26% from the latest price.
News
Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
Leading Chinese drugmakers with global ambitions such as Jiangsu Hengrui Pharmaceuticals and CanSino Biologics are struggling to recruit internationally experienced staff needed to develop and commer...
CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
DUBAI, Feb. 9, 2026 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (W...
CanSino Biologics CEO on earnings, business outlook, and international partnerships
Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global market. He also says the impact...
CanSino CEO on China's Pharma Outlook
Xuefeng Yu, Co-founder, CEO and Chairman at CanSino Biologics, discusses the company's business strategy and outlook for China's pharmaceutical sector. He speaks with Stephen Engle on the sidelines of...
China 'Definitely' Needs 2nd Covid Booster Dose: CanSino Biologics CEO
Yu Xuefeng, chief executive officer of CanSino Biologics Inc., a Tianjin, China-based drugmaker that's rolling out a vaccine that can be inhaled, discusses the supply-demand outlook in the country. He...
World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.
GALWAY, Ireland--(BUSINESS WIRE)--Late in 2021, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) announced a development and commercial supply partnership for th...
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots.
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
TIANJIN, China , May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use List...
CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research
TIANJIN, China , April 24, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: , HKEX: 06185) today announced its new brand identity, which is intended to represent the C...
CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China
TIANJIN, April 3, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China ("NM...
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia
TIANJIN, China, March 22, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector...
Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant
TIANJIN, China, March 13, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that medRxiv, a preprint platform for preliminary biomedical research, p...
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China
TIANJIN, China, Feb. 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)...
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that Preprints with The Lancet, a collaboration between the research shar...
COVID shot drives CanSinoBIO's first six-month profit since at least 2019
Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of it...
Jim Cramer breaks down the stocks of companies in the race to develop a coronavirus vaccine
"Mad Money" host Jim Cramer on Thursday broke down the different companies trying to develop a coronavirus vaccine, offering insights for investors who want to buy their stocks.
Here Are All the COVID-19 Vaccines Currently in Clinical Testing
Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.
CanSino Biologics' Covid-19 Vaccine Shows Early Promise
A vaccine against Covid-19 from a Chinese company showed promise in early-stage testing, according to an article in Lancet.